Bio-Rad reports Q1 EPS $2.54, consensus $1.78

Reports Q1 revenue $585.4M, consensus $573.23M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and Chief Executive Officer, stated: “We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives.”